Plantibodies: A New Approach for Immunomodulation in Human Health

Himani Punia¹ and Anurag Malik*²

Received: November 04, 2018;   Published: November 19, 2018

DOI: 10.26717/BJSTR.2018.11.002061

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Antibodies or immunoglobulins are the vital component of adaptive immune system in mammals. These are mainly present in the body fluid and constitute an assembly of glycoproteins released by B-cells. B-cells constitute the humoral type of adaptive immune system. They are highly specific their mode of action. First they recognize their target specifically, binds to the antigen/toxin of pathogen and produce and elicit the immune response. These features permit immunoglobulins to be employed in diverse range of applications such as diagnosis, prevention and treatment [1]. Production of defective antibody response results in increased vulnerability to pyogenic infections due to impairment in B-cell function, e.g. in hyper-IgM syndrome as a result of improper signaling between B and T cells and in X-linked agammaglobulinemia. To overcome these defects, constant region of a human immunoglobulin is modified by transgenic approach to create recombinant antibody [2]. With this advancement, a new expectation of a reliable, inexpensive cure for diseases like, diabetes and cancer was awakening; but the major drawback was its cost ineffectiveness.